Introduction: Cost-effectiveness analysis (CEA)
INTRODUCTION
Current economic assessment of a new medical intervention such as a drug, device, or vaccine aims to provide local decision makers with information on the additional benefit generated for the additional cost incurred, compared with the existing situation [1, 2] . This is most commonly conducted using costeffectiveness analysis (CEA), with results expressed with incremental cost-effectiveness ratios (ICERs). The ICER can be used to help define an acceptable ''value-based'' price range for the new intervention, with the maximum acceptable price being the price at which the ICER crosses a defined threshold [2] . The gross domestic product (GDP) per capita is a wellaccepted threshold measure, as proposed and recommended by the World Health
Organization (WHO) [3, 4] . If the price of the new technology leads to an ICER below the threshold, that price is qualified as being highly cost-effective following the interpretation of the WHO guidelines [5] .
CEA is a well-established economic assessment technique in healthcare [6] [7] [8] . It was initially developed in industrialized countries with mature healthcare systems which had already made considerable investments in healthcare infrastructure. More recently, the use of CEA has been extended to economic evaluations of health interventions in developing countries. For example, CEA results for rotavirus vaccination have been reviewed in developed countries [9] and developing countries [10] . These two reviews reported that the vaccine was very cost-effective in lowincome countries, but the picture was mixed in high-income countries. A similar result was reported by Rheingans et al. [11] comparing the cost-effectiveness and price setting of rotavirus vaccination for different country groups in Latin America from low income (L), via low middle (LM), to upper middle income (UM).
They reported that the price per vaccine dose that is cost-effective was higher in L countries than in LM and UM countries. This is counterintuitive, as it would be expected that the maximum price for favorable cost-effectiveness would be lower in L countries, reflecting the lower income and lower resources available for healthcare, compared with higher-income countries. The authors of these papers did not attempt to explain this paradoxical finding. The analysis provided here builds on these previous reports by seeking to explore how these apparently paradoxical results could arise. This paper focuses on rotavirus vaccination as an example. It is an interesting example, as the rotavirus vaccine has been the subject of CEA in a range of countries worldwide, and the benefits obtained from the vaccine appear quite different in high-versus low-income countries [12] . In low-income countries, the benefit of vaccination is primarily a reduction in the high mortality rate. In high-income countries, in addition to a reduced need for hospital care the benefits are more subtle, such as better time management for working parents [11, 13] .
In this paper, first a theoretical framework and interpretation of the ''value-based'' price range is presented for a new vaccine program. In the next step, an application in practice for rotavirus vaccination using published countryspecific data for rotavirus to estimate the ''valuebased'' price range in nine countries was conducted. This allowed an analysis of the relationship of the ''value-based'' price range for each country and the GDP/capita. Finally, the findings are interpreted and recommendations made for alternative/ additional economic evaluations.
METHODS

Compliance with Ethics Guidelines
This article does not contain any new studies with human or animal subjects performed by any of the authors.
Theoretical Framework
The first step demonstrates, using mathematical equations, the relationship between the price of a new intervention, the ICER, the threshold value for cost-effectiveness, and the cost neutral This relationship is now considered within the context of a static cohort model for modeling the cost-effectiveness of the intervention of the rotavirus vaccine [14] . Additional equations and variables help to specify which exact parameters define the slope of the line (a) and which the intercept (b) that is the remaining disease cost after the impact of the new intervention divided by the difference in disease outcomes attributable to the new intervention. Calculating the association between the price of the new intervention and the ICER allows testing the price range over which it is still costeffective. This is defined here as the price range for which the ICER lies below the threshold value, defined as 1 9 GDP per capita [3] . The linear function also indicates at what price the ICER equals zero (because of no difference in total cost with the intervention compared with the total cost without the intervention). This is referred to as the cost neutral price (Pn). The maximum price (Pm) above which a new product is no longer cost-effective is defined by the point where the threshold value intersects with the increasing linear function for new interventions that are more effective but result in higher total costs than with the current health care program (see Fig. 1 ). Now, we further elaborate on the mathematical properties of the relationship Fig. 1 Cost neutral (Pn) and maximum price (Pm) of the vaccine per dose at a threshold T (e.g., $40,000/life-year gained). a Slope, b intercept, CostV vaccine cost, GDP gross domestic product, ICER incremental cost-effectiveness ratio, Pm maximum price, Pn cost neutral price, T threshold described above. In its simplest form, the relationship between the ICER and the cost (price) of a new intervention (vaccine) is defined by the following equations: There is one additional variable to be defined in the equations, the vaccine impact on diseaserelated costs and negative health outcomes:
where:
• the coverage rate affects both sides of the ratio (higher coverage results in both higher costs and higher effect). Table 1 summarizes the input values selected.
The baseline value for CostD NV was $60/ subject, calculated from data in studies in a recent literature review [9] . It represents the average cost for rotavirus hospitalization in Europe per child in the birth cohort (i.e., the total cost of rotavirus hospitalizations averaged across all children in the cohort). As only a small percentage of children in the birth cohort will be hospitalized for rotavirus, the cost per subject is much smaller than the cost per hospitalized case or per hospitalization event.
The baseline value for E NV (0.00031/subject) is based on the following reasoning. The maximum individual loss in health outcome is the loss of full life expectancy at birth (78 years, discounted at 3% per year = 31 years). That value is multiplied by the disease-specific mortality rate (0.00001 per year) for infants in the region to estimate the individual loss in health outcomes per unvaccinated subject in the infant population. The perspective is that of the healthcare system. Figure 2 shows how the vaccine price range (Pm-Pn) can shift and change for countries with different cost-effectiveness thresholds but also CostD NV $60
CostV at Pn CostD NV -CostD v $54 with a low disease burden (indicated by the steeper slope) and a higher current expenditure on the disease (Pn and Pm both shifted to the right). Thus, the slope of the line is likely to be steeper and the absolute difference between Pn and Pm is lower for countries with a higher GDP/capita associated with a lower disease burden and higher disease expenditures in the absence of vaccination (see Fig. 2 ).
Country-Specific Data
The next step is to apply this theoretical approach to real-life published data from nine countries across the world for which the costeffectiveness of rotavirus vaccine has been evaluated using a similar model [15] , taking the country-specific GDP per capita as the threshold value. The model adjusts for different current disease-related costs and different vaccine impacts in high-income and low-income countries, and for other factors related to country-specific conditions such as life expectancy, unit cost (expressed in $), disease management, and GDP, among others.
Effects are consistently discounted at 3% per year. The same current intervention CostD NV (hospitalization) and E NV (disease-specific mortality) variables are used as in the base case model. Cost variables were not discounted because of the short period (the first 2-3 years) when health care expenditure on vaccination and disease-related cost occurs.
RESULTS
Hypothetical Baseline Model Table 1 
Country-Specific Data
For each country, country-specific values for the variables of current cost (CostD NV ) and loss in , and the blue line a country with a high threshold (T1). As the threshold increases the cost neutral point (where the line intercepts the x-axis) shifts to the right and the slope steepens, reflecting higher healthcare expenditure and lower remaining disease burden. CostV vaccine cost, ICER incremental cost-effectiveness ratio, P nHC cost neutral price in high-income country, P nLC cost neutral price in lowincome country, P nMC cost neutral price in middle-income country, T threshold health outcomes (E NV ) were used to calculate the Pn and Pm of the vaccine at the countryspecific threshold (GDP per capita). This exercise provides a better understanding of the meaning of a cost-effectiveness result for countries with different income levels, expressed through their GDP values. Table 2 presents the input data for each country, obtained from published sources as follows:
Vietnam [16] , Egypt [17] , Philippines [18] , Algeria [19] , Turkey [20] , Portugal [21] , France [15] , The Netherlands [22] , and Norway [23] .
Life expectancy data for all countries were obtained from WHO Health Statistics 2013 [24] , and GDP per capita from World Bank data [5] . Table 2 also shows the CostD NV and E NV per subject with the calculated Pn and Pm at the GDP threshold for each country. Figure 3 presents the relationship between Pm and GDP per capita across the nine countries, plotted from the data in Table 2 . It shows that the countries fall into two groups for the relationship between Pm and the countryspecific GDP threshold values. For the cluster of countries with a GDP per capita [$10,000, the lower the GDP threshold, the lower the Pm. In this group of countries, the slope is steep, with a fairly narrow range between Pn and Pm (see Table 2 ). threshold. This is because as the disease burden at baseline increases with the increasing number of deaths, the benefit of the vaccine in reducing the disease burden will also be higher in absolute value, the slope of the line in Fig. 4 will be lower and therefore the price range over which the vaccine is cost-effective will be larger. The vaccine price range for costeffectiveness (Pm-Pn) is, however, much larger in Norway than in Portugal, despite a disease burden that is 1.3 times lower in Norway than Portugal.
In the second cluster of countries, those with a low GDP per capita, the pattern of systematic decline of the Pm with lower GDP per capita no longer fits the data. The baseline disease-related healthcare costs are so low (CostD NV ), and the remaining health burden (E NV ) so high that the slope factor 'a' is also very low (see Table 2 ). The slope factor is given by the equation:
The slope angle is very shallow because of the high reduction in losses in health outcomes, and the Pn value is close to zero because of the low current expenditure per case for the disease and thus the potential for only minimal cost offsets. The maximum price in this group of countries is strongly influenced by the threshold value (GDP per capita) and the remaining disease burden in the absence of vaccination. As the threshold value increases, the maximum price also increases. In addition, as the disease burden in the absence of vaccination increases, the slope of the line decreases and the maximum price increases even without a change in the threshold, as illustrated in the present analysis using Norway and Portugal as examples. Fig. 4 Effect on the maximum price (Pm) of increasing the threshold (GDP in Norway compared with Portugal) and increasing the disease burden (number of rotavirus deaths per year in Portugal increased from P1 to P2 to P3). CostV Vaccine cost, GDP gross domestic product, ICER incremental cost-effectiveness ratio, Pm maximum price, T N threshold for Norway, T P threshold for Portugal
Countries with Low GDP/Capita
The situation is quite different when conducting CEA outside mature healthcare markets. This reflects an environment with low existing healthcare investment (CostD NV ) and high disease burden (E NV ) as a consequence. The low existing healthcare expenditure on the disease allows minimal scope for cost offsets, so the Pn is close to zero. The high disease burden has the potential for large reductions in health outcome losses, so an effective intervention can be cost-effective (as defined by the GDP per capita threshold) over a wide price range, because of the low slope.
This wide price range within which rotavirus vaccination is cost-effective offers a possible explanation for the paradoxical results for rotavirus vaccination CEA reported in the literature. Reviews of rotavirus vaccination reported high cost-effectiveness in low-income countries and a mixed picture in high-income countries [10] . A study in Latin America found that the vaccine price that was apparently costeffective was higher in low-income countries than in middle-income countries [11] . Yet, it is clear that high prices are not affordable or acceptable for low-income countries. The present analysis suggests that the apparently better cost-effectiveness results at a relatively high intervention price in countries with low GDP per capita reflects the large increases in health outcomes possible in such environments.
In situations with high potential increases in health outcomes accompanied by low current health care expenditures, ICER values calculated by conventional CEA have limited value in defining a reasonable price band for a new intervention. Even if the estimated ICER value indicates that a high price would be costeffective based on a 1 9 GDP threshold, the price may be rejected on the basis of the affordability of the acquisition cost [27] . A price close to the Pn is likely to be preferred by the low-income country, but as the Pn is likely to be very low (because low existing healthcare expenditure offers minimal scope for cost offsets), such a price might not be seen as reasonable by the seller of the new intervention. Thus, if Pn and Pm define price bands in low-income countries that are questionable at the extremes for both payers and producers, CEA performed under these conditions might not be able to serve the same function in low-income countries as in high-income countries, where CEA is used to help define a reasonable price band.
Although the value of $10,000 GDP per capita that differentiates the two groups of countries in this analysis is an arbitrary threshold, it acts as a proxy for the degree of healthcare development in a country. Countries in the group with a high GDP per capita typically have well-established healthcare systems with infrastructure already in place. In these countries, the fixed cost of healthcare infrastructure is already accounted for and variable costs for treatment are well accepted.
In these cases, decisions about new interventions can be made at the margin using incremental costs and benefits for individuals, as described in the ICER calculated by conventional CEA that assumes that prices are a fair representation of opportunity costs. 
Potential Future Directions
Our results suggest that CEA is not necessarily the optimum economic analysis method for defining a feasible price band for a new intervention in low-income countries [28] .
Measuring shadow prices could be an alternative if cost-benefit analysis or CEA is used for economic assessment of new interventions in those situations [29] . In lowincome environments with low health investment and a high disease burden, almost any improvement in health will require extra spending. The question therefore should be phrased not as a comparison of the new intervention with the existing situation which could be considered as a substitution economy, but as a consideration of which alternative interventions would provide the greatest additional health benefit for a given amount of extra money spent-an add-on economy instead of substitution [30] .
Health problems that affect a whole population (as is often the case in low-income countries) should be assessed using economic approaches, tools or techniques that describe the problem well at the population level. In addition, the impact of increased spending on health care on other sectors of the economy should be included in the analyses.
Budget optimization modeling (BOM) [31] and return on investment (ROI) [17] ROI analysis is also attractive. It is based on the premise that the health problem must be substantial at population level and compares different investment policies in terms of benefit within that population projected over time as a function of tax payment/income for the government. It can compare investment in prevention through vaccination with either doing nothing or increasing healthcare infrastructure to reach the same health benefit level. However, a limitation is that it considers health benefits only in terms of the effects on future tax revenues, and does not take into account intangible benefits such as the improvement in human welfare arising from reductions in the disease burden.
A further area of uncertainty is whether the average GDP per capita reflects the right threshold value [33] . First, the distribution of GDP per capita in low-income countries is often skewed, and much of the population may receive little benefit from any healthcare services offered because they do not have access to them. This issue is not reflected in the average per-capita GDP value, but is reflected in the remaining health problem (E NV ). For example, Egypt has a relatively high GDP per capita, close to the value reported for Algeria, while the disease burden (E NV ) is high and comparable with populations such as the Philippines (see Table 2 ). Second, GDP per capita does not necessarily relate to the investment a country is willing to make in healthcare, which may be affected by other competing priorities.
The present analysis has limitations. Not all the different costs and benefits related to rotavirus vaccination have been included in the analysis, as the focus was only on the parameters that drive the main results, hospitalization and mortality. However, a more detailed assessment is not likely to change the main discrepancy between the clusters of countries with high versus low income. Furthermore, the analysis has only investigated a single intervention and disease, rotavirus vaccination. The next step would be to explore whether other disease areas show similar patterns, which would indicate whether the findings are likely to be generalizable.
CONCLUSION
The paradoxical results of CEA in countries with low GDP per capita described in this paper suggest that conventional CEA may have limited applicability for defining an acceptable price range in such situations. This may be because current methods for cost-effectiveness analyses do not properly account for the opportunity costs of the new intervention in low-income countries. Alternative economic methods may be better suited to the economic assessment of healthcare interventions in lowincome countries, and this should be explored in greater detail.
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